PhilipGreysonBlackMD
Pediatric Pulmonology • Kansas City, MOAssociate Professor, Pediatrics, University of Missouri, Kansas City School of Medicine
Dr. Black is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2401 Gillham Rd
Kansas City, MO 64108Phone+1 816-234-3000
Education & Training
University of Utah HealthResidency, Pediatrics, 1983 - 1984
Tulane UniversityResidency, Pediatrics, 1982 - 1983- University of Utah HealthResidency, Pediatrics, 1981 - 1982
University of Kansas School of MedicineInternship, Transitional Year, 1979 - 1980- University of Kansas School of MedicineClass of 1979
Certifications & Licensure
UT State Medical License 1900 - Present
MO State Medical License 1990 - 2025
KS State Medical License 1990 - 2022
TX State Medical License 1988 - 1990
LA State Medical License 1982 - 1983- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
- OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
- Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) Start of enrollment: 2016 Oct 21
Publications & Presentations
PubMed
- 26 citationsLong-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR ...Patrick A. Flume, Reta Fischer Biner, Damian G Downey, Cynthia A. Brown, Manu Jain
The Lancet. Respiratory Medicine. 2021-02-10 - 70 citationsAzithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized TrialNicole Mayer-Hamblett, George Z. Retsch-Bogart, Margaret Kloster, Frank J. Accurso, Margaret Rosenfeld
American Journal of Respiratory and Critical Care Medicine. 2018-11-01 - 30 citationsChanges in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.Felix Ratjen, Michelle Klingel, Philip Black, Michael R. Powers, Hartmut Grasemann
American Journal of Respiratory and Critical Care Medicine. 2018-08-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
